RESUMO
In response to the SARSCoV2 outbreak, and the resulting COVID19 pandemic, a global competition to develop an antiCOVID19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether shortterm, midterm, and longterm vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccineinduced mechanisms that have demonstrated adverse effects based on previous clinical trials and laboratory research. It presents scientific evidence of potential pitfalls associated with eliminating critical phase II and III clinical trials, and concludes that there is no substitute currently available for longterm human clinical trials to ensure longterm human safety.